Back to Depression And Anxiety
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00595699

NCT00595699
Completed Phase 4

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with temporal lobe epilepsy.
  • You have been diagnosed with Major Depression (based on standard medical criteria called DSM-IV).
  • Your depression score on a standard rating scale (called the MADRS) is 15 or higher at both your screening and baseline appointments.
  • You are between 18 and 65 years old.
  • If you are a woman who could become pregnant, you are willing and able to use an effective form of contraception (such as a condom with diaphragm, or a diaphragm with spermicide, or another method with a very low failure rate).
  • You are willing to sign a consent form agreeing to take part in the study voluntarily.

Who may not be able to join:

  • You have a diagnosed mental health condition other than Major Depression (confirm with trial site).
  • Your seizures have been identified as psychological rather than caused by epilepsy (known as non-epileptic seizures).
  • You have previously tried two or more antidepressant medications at full doses without them working.
  • You have had problems with alcohol or drug misuse or dependence in the past six months.
  • You have a serious medical condition affecting your heart, liver, or kidneys, or you are significantly malnourished.
  • You are currently pregnant or breastfeeding.
  • You have or are suspected to have an intellectual disability, a psychotic disorder, or dementia.
  • You take a seizure medication called phenobarbital.
  • You need to take certain medications that affect mood or anxiety, such as benzodiazepines (confirm with trial site for the full list).
  • You are currently receiving a type of talking therapy called cognitive-behavioral therapy (CBT), or you plan to start it during the study. Other types of therapy may be allowed if you have already been attending regularly for at least 12 weeks and plan to continue throughout the study.
  • The study doctor believes you would have difficulty understanding or following the study requirements.
  • You have a known allergy or sensitivity to the medication escitalopram or any of its ingredients.
  • The study doctor believes you are at significant risk of suicide, or you have made a serious suicide attempt in the past two years.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 4: approximately Approved of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 4
Sponsor
Conrad, Erich J., M.D.
Registry
clinicaltrials_gov
Start date
1 November 2006
Est. completion
1 December 2009

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Montgomery And Asberg Depression Rating Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov